Arcellx, Inc.
US ˙ NasdaqGS ˙ US03940C1009

Introduction

This page provides a comprehensive analysis of the known insider trading history of Sonsini Peter W.. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

See Highest Ranking Insiders
Companies with Reported Insider Positions

The SEC filings indicate Sonsini Peter W. has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:OYST / Oyster Point Pharma Inc 10% Owner 0
US:ACLX / Arcellx, Inc. 10% Owner 12
US:AKUS / Akouos Inc 10% Owner 0
10% Owner 70
US:AVEO / AVEO Pharmaceuticals Inc 10% Owner 24
US:ZFOX / ZeroFox Holdings, Inc. 10% Owner 18,068,513
US:SNTI / Senti Biosciences, Inc. 10% Owner 4,426,151
US:GNCA / Genocea Biosciences Inc 10% Owner 0
US:HOOD / Robinhood Markets, Inc. Director 270
US:TRVI / Trevi Therapeutics, Inc. 10% Owner 3,000,000
US:IMRA / Bitwise Funds Trust - Bitwise MARA Option Income Strategy ETF 10% Owner 2,611,050
US:CSPR / Casper Sleep Inc 10% Owner 0
US:BHG / Bright Health Group, Inc. 10% Owner 125,000
US:MTCR / Metacrine Inc 10% Owner 2,563,257
US:BGRY / Berkshire Grey Inc - Class A 10% Owner 38,183,023
US:GLUE / Monte Rosa Therapeutics, Inc. 10% Owner 0
10% Owner 54
US:EAR / Eargo, Inc. 10% Owner 821
US:RPHM / Reneo Pharmaceuticals, Inc. 10% Owner 0
US:MRKR / Marker Therapeutics, Inc. 10% Owner 10,714,285
US:SVRA / Savara Inc. 10% Owner 24,137,931
US:VRNA / Verona Pharma plc - Depositary Receipt (Common Stock) 10% Owner 9,757,393
US:RGLS / Regulus Therapeutics Inc. 10% Owner 258,707
US:MRSN / Mersana Therapeutics, Inc. 10% Owner 745
US:INZY / Inozyme Pharma, Inc. 10% Owner 2,437,689
US:NKTX / Nkarta, Inc. 10% Owner 0
US:SURF / Surface Oncology Inc 10% Owner 2,892,877
US:CSBR / Champions Oncology, Inc. 10% Owner 0
US:ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) 10% Owner 19,500,000
US:ARDX / Ardelyx, Inc. 10% Owner 3,482,186
US:GRTX / Galera Therapeutics, Inc. 10% Owner 0
US:MIRM / Mirum Pharmaceuticals, Inc. 10% Owner 0
US:NITE / Capitol Series Trust - The Nightview Fund 10% Owner 0
US:TPST / Tempest Therapeutics, Inc. 10% Owner 3,532,814
US:MULE / Mulesoft, Inc. 10% Owner 0
US:TCON / TRACON Pharmaceuticals, Inc. 10% Owner 707,964
US:CASC / Cascadian Therapeutics, Inc. 10% Owner 0
US:ABIO / ARCA biopharma, Inc. 10% Owner 0
US:APPN / Appian Corporation 10% Owner 0
US:SYBX / Synlogic, Inc. 10% Owner 4,228,940
US:SBBP / Strongbridge Biopharma plc 10% Owner 8,282,616
US:ASNS / Actelis Networks, Inc. 10% Owner 4,000,000
US:AKAO / Achaogen, Inc. 10% Owner 5,215,128
US:ILIU / Interleukin Genetics, Inc. 10% Owner 20,120,724
US:AVTX / Avalo Therapeutics, Inc. 10% Owner 0
US:LOXO / Loxo Oncology, Inc. 10% Owner 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Sonsini Peter W.. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ACLX / Arcellx, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACLX / Arcellx, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2022-06-21 ACLX New Enterprise Associates 15, L.P. 312,500 16.0000 312,500 16.0000 5,000,000 323 46.8950 9,654,688 193.09
2022-02-08 ACLX New Enterprise Associates 15, L.P. 1,583,333 15.0000 1,583,333 15.0000 23,749,995

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ACLX / Arcellx, Inc. Insider Trades
Insider Sales ACLX / Arcellx, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACLX / Arcellx, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ACLX / Arcellx, Inc. Insider Trades
Insider Purchases ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACLX / Arcellx, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2020-01-24 ADAP Sonsini Peter W. 7,500,000 0.6667 7,500,000 0.6667 5,000,250 130 12.1000 85,749,750 1,714.91

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) Insider Trades
Insider Sales ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACLX / Arcellx, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ADAP / Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) Insider Trades
Insider Purchases APPN / Appian Corporation - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACLX / Arcellx, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

APPN / Appian Corporation Insider Trades
Insider Sales APPN / Appian Corporation - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACLX / Arcellx, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

APPN / Appian Corporation Insider Trades
Insider Purchases ARDX / Ardelyx, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACLX / Arcellx, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ARDX / Ardelyx, Inc. Insider Trades
Insider Sales ARDX / Ardelyx, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACLX / Arcellx, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ARDX / Ardelyx, Inc. Insider Trades
Insider Purchases AVTX / Avalo Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACLX / Arcellx, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

AVTX / Avalo Therapeutics, Inc. Insider Trades
Insider Sales AVTX / Avalo Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACLX / Arcellx, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

AVTX / Avalo Therapeutics, Inc. Insider Trades
Insider Purchases CSBR / Champions Oncology, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACLX / Arcellx, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CSBR / Champions Oncology, Inc. Insider Trades
Insider Sales CSBR / Champions Oncology, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACLX / Arcellx, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
2020-03-06 CSBR New Enterprise Associates 14, L.P. 708,155 6.9900 708,155 6.9900 4,950,003 6 4.19 -1,982,834 -40.06

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CSBR / Champions Oncology, Inc. Insider Trades
Insider Purchases GLUE / Monte Rosa Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACLX / Arcellx, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

GLUE / Monte Rosa Therapeutics, Inc. Insider Trades
Insider Sales GLUE / Monte Rosa Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACLX / Arcellx, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

GLUE / Monte Rosa Therapeutics, Inc. Insider Trades
Insider Purchases GNCAQ / Genocea Biosciences, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACLX / Arcellx, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

GNCAQ / Genocea Biosciences, Inc. Insider Trades
Insider Sales GNCAQ / Genocea Biosciences, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACLX / Arcellx, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

GNCAQ / Genocea Biosciences, Inc. Insider Trades
Insider Purchases GRTX / Galera Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACLX / Arcellx, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2019-11-12 GRTX New Enterprise Associates 14, L.P. 416,666 12.0000 416,666 12.0000 4,999,992 111 17.67 2,362,496 47.25

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

GRTX / Galera Therapeutics, Inc. Insider Trades
Insider Sales GRTX / Galera Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACLX / Arcellx, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

GRTX / Galera Therapeutics, Inc. Insider Trades
Insider Purchases HOOD / Robinhood Markets, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACLX / Arcellx, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

HOOD / Robinhood Markets, Inc. Insider Trades
Insider Sales HOOD / Robinhood Markets, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACLX / Arcellx, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

HOOD / Robinhood Markets, Inc. Insider Trades
Insider Purchases IMRA / Bitwise Funds Trust - Bitwise MARA Option Income Strategy ETF - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACLX / Arcellx, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2020-03-16 IMRA New Enterprise Associates 14, L.P. 475,000 16.0000 118,750 64.0000 7,600,000 87 54.87 -1,084,188 -14.27

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IMRA / Bitwise Funds Trust - Bitwise MARA Option Income Strategy ETF Insider Trades
Insider Sales IMRA / Bitwise Funds Trust - Bitwise MARA Option Income Strategy ETF - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACLX / Arcellx, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
2022-04-06 IMRA New Enterprise Associates 14, L.P. 255,463 1.1032 63,866 4.4128 281,827 6 0.9900 -218,600 -77.57
2022-04-05 IMRA New Enterprise Associates 14, L.P. 439,088 1.0691 109,772 4.2764 469,429
2022-01-25 IMRA New Enterprise Associates 14, L.P. 102,952 1.4745 25,738 5.8980 151,803
2022-01-24 IMRA New Enterprise Associates 14, L.P. 19,984 1.5521 4,996 6.2084 31,017
2022-01-21 IMRA New Enterprise Associates 14, L.P. 11,622 1.6683 2,906 6.6732 19,389
2022-01-20 IMRA New Enterprise Associates 14, L.P. 6,295 1.8086 1,574 7.2344 11,385
2022-01-19 IMRA New Enterprise Associates 14, L.P. 13,412 1.8203 3,353 7.2812 24,414
2022-01-18 IMRA New Enterprise Associates 14, L.P. 6,848 1.8877 1,712 7.5508 12,927
2022-01-14 IMRA New Enterprise Associates 14, L.P. 9,707 1.9144 2,427 7.6576 18,583
2022-01-13 IMRA New Enterprise Associates 14, L.P. 7,209 1.9262 1,802 7.7048 13,886
2022-01-12 IMRA New Enterprise Associates 14, L.P. 4,634 2.0193 1,158 8.0772 9,357
2022-01-11 IMRA New Enterprise Associates 14, L.P. 2,409 2.0421 602 8.1684 4,919
2022-01-10 IMRA New Enterprise Associates 14, L.P. 1,751 2.0000 438 8.0000 3,502
2022-01-07 IMRA New Enterprise Associates 14, L.P. 14,600 2.0766 3,650 8.3064 30,318
2022-01-06 IMRA New Enterprise Associates 14, L.P. 10,257 2.1649 2,564 8.6596 22,205
2022-01-05 IMRA New Enterprise Associates 14, L.P. 8,200 2.2487 2,050 8.9948 18,439
2022-01-04 IMRA New Enterprise Associates 14, L.P. 13,459 2.3437 3,365 9.3748 31,544
2022-01-03 IMRA New Enterprise Associates 14, L.P. 44,665 2.3373 11,166 9.3492 104,396
2021-12-31 IMRA New Enterprise Associates 14, L.P. 49,953 2.2503 12,488 9.0012 112,409
2021-12-30 IMRA New Enterprise Associates 14, L.P. 21,858 2.2905 5,464 9.1620 50,066
2021-12-29 IMRA New Enterprise Associates 14, L.P. 15,196 2.3002 3,799 9.2008 34,954
2021-12-28 IMRA New Enterprise Associates 14, L.P. 24,580 2.3409 6,145 9.3636 57,539
2021-12-27 IMRA New Enterprise Associates 14, L.P. 27,651 2.4233 6,913 9.6932 67,007
2021-12-23 IMRA New Enterprise Associates 14, L.P. 23,961 2.4100 5,990 9.6400 57,746
2021-12-22 IMRA New Enterprise Associates 14, L.P. 20,109 2.3213 5,027 9.2852 46,679
2021-12-21 IMRA New Enterprise Associates 14, L.P. 41,222 2.3241 10,306 9.2964 95,804
2021-12-20 IMRA New Enterprise Associates 14, L.P. 47,000 2.2103 11,750 8.8412 103,884
2021-12-20 IMRA New Enterprise Associates 14, L.P. 38,123 2.3272 9,531 9.3088 88,720
2021-12-16 IMRA New Enterprise Associates 14, L.P. 44,993 2.2347 11,248 8.9388 100,546
2021-12-15 IMRA New Enterprise Associates 14, L.P. 28,817 2.2794 7,204 9.1176 65,685
2021-12-14 IMRA New Enterprise Associates 14, L.P. 15,093 2.5603 3,773 10.2412 38,643
2021-12-13 IMRA New Enterprise Associates 14, L.P. 17,501 2.8317 4,375 11.3268 49,558
2021-12-10 IMRA New Enterprise Associates 14, L.P. 8,667 2.8316 2,167 11.3264 24,541
2021-12-09 IMRA New Enterprise Associates 14, L.P. 5,666 2.9462 1,416 11.7848 16,693

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IMRA / Bitwise Funds Trust - Bitwise MARA Option Income Strategy ETF Insider Trades
Insider Purchases MIRM / Mirum Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACLX / Arcellx, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MIRM / Mirum Pharmaceuticals, Inc. Insider Trades
Insider Sales MIRM / Mirum Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACLX / Arcellx, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MIRM / Mirum Pharmaceuticals, Inc. Insider Trades
Insider Purchases MRKR / Marker Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACLX / Arcellx, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MRKR / Marker Therapeutics, Inc. Insider Trades
Insider Sales MRKR / Marker Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACLX / Arcellx, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MRKR / Marker Therapeutics, Inc. Insider Trades
Insider Purchases MRSN / Mersana Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACLX / Arcellx, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
2019-03-05 MRSN New Enterprise Associates 14, L.P. 3,750,000 4.0000 150,000 100.0000 15,000,000 358 9.2800 -13,608,000 -90.72

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MRSN / Mersana Therapeutics, Inc. Insider Trades
Insider Sales MRSN / Mersana Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACLX / Arcellx, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
2019-08-28 MRSN New Enterprise Associates 14, L.P. 1,211 2.9100 48 72.7500 3,524 40 1.4500 -3,454 -98.02

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MRSN / Mersana Therapeutics, Inc. Insider Trades
Insider Purchases MSTX / Tidal Trust II - Defiance Daily Target 2X Long MSTR ETF - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACLX / Arcellx, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MSTX / Tidal Trust II - Defiance Daily Target 2X Long MSTR ETF Insider Trades
Insider Sales MSTX / Tidal Trust II - Defiance Daily Target 2X Long MSTR ETF - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACLX / Arcellx, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

MSTX / Tidal Trust II - Defiance Daily Target 2X Long MSTR ETF Insider Trades
Insider Purchases NITE / Capitol Series Trust - The Nightview Fund - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACLX / Arcellx, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

NITE / Capitol Series Trust - The Nightview Fund Insider Trades
Insider Sales NITE / Capitol Series Trust - The Nightview Fund - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACLX / Arcellx, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

NITE / Capitol Series Trust - The Nightview Fund Insider Trades
Insider Purchases NKTX / Nkarta, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACLX / Arcellx, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

NKTX / Nkarta, Inc. Insider Trades
Insider Sales NKTX / Nkarta, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACLX / Arcellx, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

NKTX / Nkarta, Inc. Insider Trades
Insider Purchases SNTI / Senti Biosciences, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACLX / Arcellx, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SNTI / Senti Biosciences, Inc. Insider Trades
Insider Sales SNTI / Senti Biosciences, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACLX / Arcellx, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SNTI / Senti Biosciences, Inc. Insider Trades
Insider Purchases SYBX / Synlogic, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACLX / Arcellx, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SYBX / Synlogic, Inc. Insider Trades
Insider Sales SYBX / Synlogic, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACLX / Arcellx, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

SYBX / Synlogic, Inc. Insider Trades
Insider Purchases TPST / Tempest Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACLX / Arcellx, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TPST / Tempest Therapeutics, Inc. Insider Trades
Insider Sales TPST / Tempest Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACLX / Arcellx, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TPST / Tempest Therapeutics, Inc. Insider Trades
Insider Purchases TRVI / Trevi Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACLX / Arcellx, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TRVI / Trevi Therapeutics, Inc. Insider Trades
Insider Sales TRVI / Trevi Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACLX / Arcellx, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

TRVI / Trevi Therapeutics, Inc. Insider Trades
Insider Purchases VRNA / Verona Pharma plc - Depositary Receipt (Common Stock) - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACLX / Arcellx, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VRNA / Verona Pharma plc - Depositary Receipt (Common Stock) Insider Trades
Insider Sales VRNA / Verona Pharma plc - Depositary Receipt (Common Stock) - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ACLX / Arcellx, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VRNA / Verona Pharma plc - Depositary Receipt (Common Stock) Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Sonsini Peter W. as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change		 Share
Price		 Tran
Value		 Remaining
Value
2023-01-04 2023-01-03 4 OYST Oyster Point Pharma, Inc.
Common Stock 		U - Other -5,925,287 0 -100.00
2022-12-22 2022-12-20 4 ACLX Arcellx, Inc.
Common Stock 		J - Other 12 12
2022-12-22 2022-12-20 4 ACLX Arcellx, Inc.
Common Stock 		J - Other 12 12
2022-12-22 2022-12-20 4 ACLX Arcellx, Inc.
Common Stock 		J - Other 12 12
2022-12-22 2022-12-20 4 ACLX Arcellx, Inc.
Common Stock 		J - Other 785 785
2022-12-22 2022-12-20 4 ACLX Arcellx, Inc.
Common Stock 		J - Other -30,000 0 -100.00
2022-12-22 2022-12-20 4 ACLX Arcellx, Inc.
Common Stock 		J - Other 30,000 30,000
2022-12-22 2022-12-20 4 ACLX Arcellx, Inc.
Common Stock 		J - Other -2,000,000 4,745,262 -29.65
2022-12-02 2022-11-30 4 AKUS Akouos, Inc.
Common Stock 		U - Other -4,294,207 0 -100.00
2022-11-18 2022-11-16 4 IONQ IonQ, Inc.
Common Stock 		J - Other 70 70
2022-11-18 2022-11-16 4 IONQ IonQ, Inc.
Common Stock 		J - Other 70 70
2022-11-18 2022-11-16 4 IONQ IonQ, Inc.
Common Stock 		J - Other 70 70
2022-11-18 2022-11-16 4 IONQ IonQ, Inc.
Common Stock 		J - Other 4,587 4,587
2022-11-18 2022-11-16 4 IONQ IonQ, Inc.
Common Stock 		J - Other -175,378 0 -100.00
2022-11-18 2022-11-16 4 IONQ IonQ, Inc.
Common Stock 		J - Other 175,378 175,378
2022-11-18 2022-11-16 4 IONQ IonQ, Inc.
Common Stock 		J - Other -11,691,864 14,614,829 -44.44
2022-10-21 2022-10-19 4 AVEO AVEO PHARMACEUTICALS, INC.
Common Stock 		J - Other 24 24
2022-10-21 2022-10-19 4 AVEO AVEO PHARMACEUTICALS, INC.
Common Stock 		J - Other 24 24
2022-10-21 2022-10-19 4 AVEO AVEO PHARMACEUTICALS, INC.
Common Stock 		J - Other 24 24
2022-10-21 2022-10-19 4 AVEO AVEO PHARMACEUTICALS, INC.
Common Stock 		J - Other 1,551 1,551
2022-10-21 2022-10-19 4 AVEO AVEO PHARMACEUTICALS, INC.
Common Stock 		J - Other -59,294 0 -100.00
2022-10-21 2022-10-19 4 AVEO AVEO PHARMACEUTICALS, INC.
Common Stock 		J - Other 59,294 59,294
2022-10-21 2022-10-19 4 AVEO AVEO PHARMACEUTICALS, INC.
Common Stock 		J - Other -3,952,957 0 -100.00
2022-10-21 2022-10-19 4 AVEO AVEO PHARMACEUTICALS, INC.
Common Stock 		J - Other -3,952,957 0 -100.00
2022-10-21 2022-10-19 4 AVEO AVEO PHARMACEUTICALS, INC.
Common Stock 		J - Other 3,952,957 3,952,957
2022-08-05 3 ZFOX ZeroFox Holdings, Inc.
Common Stock 		18,068,513
2022-06-23 2022-06-21 4 ACLX Arcellx, Inc.
Common Stock 		P - Purchase 312,500 6,745,262 4.86 16.00 5,000,000 107,924,192
2022-06-15 3 SNTI Senti Biosciences, Inc.\
Common Stock 		4,426,151
2022-05-31 2022-05-31 4 IONQ IonQ, Inc.
Common Stock 		S - Sale -498,614 26,306,693 -1.86 5.65 -2,815,374 148,538,111
2022-05-31 2022-05-27 4 IONQ IonQ, Inc.
Common Stock 		S - Sale -1,497,733 26,805,307 -5.29 5.93 -8,880,359 158,934,026
2022-05-31 2022-05-26 4 IONQ IonQ, Inc.
Common Stock 		S - Sale -926,619 28,303,040 -3.17 5.80 -5,377,726 164,259,523
2022-05-26 2022-05-25 4 GNCA GENOCEA BIOSCIENCES, INC.
Common Stock 		S - Sale -4,445,093 0 -100.00 0.08 -362,720
2022-05-26 2022-05-24 4 GNCA GENOCEA BIOSCIENCES, INC.
Common Stock 		S - Sale -5,931,843 4,445,093 -57.16 0.07 -387,943 290,709
2022-05-04 2022-05-02 4 HOOD Robinhood Markets, Inc.
Class A Common Stock 		J - Other 131 270 94.24
2022-05-04 2022-05-02 4 HOOD Robinhood Markets, Inc.
Class A Common Stock 		J - Other 131 270 94.24
2022-05-04 2022-05-02 4 HOOD Robinhood Markets, Inc.
Class A Common Stock 		J - Other 131 270 94.24
2022-05-04 2022-05-02 4 HOOD Robinhood Markets, Inc.
Class A Common Stock 		J - Other 8,551 17,670 93.77
2022-05-04 2022-05-02 4 HOOD Robinhood Markets, Inc.
Class A Common Stock 		J - Other -30,431 0 -100.00
2022-05-04 2022-05-02 4 HOOD Robinhood Markets, Inc.
Class A Common Stock 		J - Other 30,431 30,431
2022-05-04 2022-05-02 4 HOOD Robinhood Markets, Inc.
Class A Common Stock 		J - Other -2,028,736 2,028,736 -50.00
2022-05-04 2022-05-02 4 HOOD Robinhood Markets, Inc.
Class A Common Stock 		J - Other -326,913 0 -100.00
2022-05-04 2022-05-02 4 HOOD Robinhood Markets, Inc.
Class A Common Stock 		J - Other 326,913 326,913
2022-05-04 2022-05-02 4 HOOD Robinhood Markets, Inc.
Class A Common Stock 		J - Other -21,794,173 21,794,172 -50.00
2022-04-13 2022-04-11 4 TRVI Trevi Therapeutics, Inc.
Pre-Funded Warrants 		P - Purchase 3,000,000 3,000,000 1.90 5,697,000 5,697,000
2022-04-13 2022-04-11 4 TRVI Trevi Therapeutics, Inc.
Common Stock 		P - Purchase 948,948 948,948 1.90 1,803,001 1,803,001
2022-04-13 2022-04-11 4 TRVI Trevi Therapeutics, Inc.
Common Stock 		P - Purchase 2,631,578 10,421,428 33.78 1.90 4,999,998 19,800,713
2022-04-07 2022-04-06 4 IMRA IMARA Inc.
Common Stock 		S - Sale -255,463 2,611,050 -8.91 1.10 -281,827 2,880,510
2022-04-07 2022-04-05 4 IMRA IMARA Inc.
Common Stock 		S - Sale -439,088 2,866,513 -13.28 1.07 -469,429 3,064,589
2022-02-09 2022-02-08 4 ACLX Arcellx, Inc.
Series C Preferred Stock 		C - Conversion -1,732,786 0 -100.00
2022-02-09 2022-02-08 4 ACLX Arcellx, Inc.
Series B-2 Preferred Stock 		C - Conversion -698,421 0 -100.00
2022-02-09 2022-02-08 4 ACLX Arcellx, Inc.
Series B-1 Preferred Stock 		C - Conversion -872,915 0 -100.00
2022-02-09 2022-02-08 4 ACLX Arcellx, Inc.
Series A Preferred Stock 		C - Conversion -1,545,307 0 -100.00
2022-02-09 2022-02-08 4 ACLX Arcellx, Inc.
Common Stock 		P - Purchase 1,583,333 6,432,762 32.65 15.00 23,749,995 96,491,430
2022-02-09 2022-02-08 4 ACLX Arcellx, Inc.
Common Stock 		C - Conversion 4,849,429 4,849,429
2022-02-01 2022-01-28 4 HOOD Robinhood Markets, Inc.
Class A Common Stock 		J - Other 139 139
2022-02-01 2022-01-28 4 HOOD Robinhood Markets, Inc.
Class A Common Stock 		J - Other 139 139
2022-02-01 2022-01-28 4 HOOD Robinhood Markets, Inc.
Class A Common Stock 		J - Other 139 139
2022-02-01 2022-01-28 4 HOOD Robinhood Markets, Inc.
Class A Common Stock 		J - Other 9,119 9,119
2022-02-01 2022-01-28 4 HOOD Robinhood Markets, Inc.
Class A Common Stock 		J - Other -52,175 0 -100.00
2022-02-01 2022-01-28 4 HOOD Robinhood Markets, Inc.
Class A Common Stock 		J - Other 30,431 52,175 139.95
2022-02-01 2022-01-28 4 HOOD Robinhood Markets, Inc.
Class A Common Stock 		J - Other -2,028,736 4,057,472 -33.33
2022-02-01 2022-01-28 4 HOOD Robinhood Markets, Inc.
Class A Common Stock 		J - Other -348,657 0 -100.00
2022-02-01 2022-01-28 4 HOOD Robinhood Markets, Inc.
Class A Common Stock 		J - Other 326,913 348,657 1,503.46
2022-02-01 2022-01-28 4 HOOD Robinhood Markets, Inc.
Class A Common Stock 		J - Other -21,794,173 43,588,345 -33.33
2022-01-26 2022-01-25 4 CSPR Casper Sleep Inc.
Common Stock 		U - Other -6,222,502 0 -100.00 6.90 -42,935,264
2022-01-25 2022-01-25 4 IMRA IMARA Inc.
Common Stock 		S - Sale -102,952 3,305,601 -3.02 1.47 -151,803 4,874,109
2022-01-25 2022-01-24 4 IMRA IMARA Inc.
Common Stock 		S - Sale -19,984 3,408,553 -0.58 1.55 -31,017 5,290,415
2022-01-25 2022-01-21 4 IMRA IMARA Inc.
Common Stock 		S - Sale -11,622 3,428,537 -0.34 1.67 -19,389 5,719,828
2022-01-20 2022-01-20 4 IMRA IMARA Inc.
Common Stock 		S - Sale -6,295 3,440,159 -0.18 1.81 -11,385 6,221,872
2022-01-20 2022-01-19 4 IMRA IMARA Inc.
Common Stock 		S - Sale -13,412 3,446,454 -0.39 1.82 -24,414 6,273,580
2022-01-20 2022-01-18 4 IMRA IMARA Inc.
Common Stock 		S - Sale -6,848 3,459,866 -0.20 1.89 -12,927 6,531,189
2022-01-14 2022-01-14 4 IMRA IMARA Inc.
Common Stock 		S - Sale -9,707 3,466,714 -0.28 1.91 -18,583 6,636,677
2022-01-14 2022-01-13 4 IMRA IMARA Inc.
Common Stock 		S - Sale -7,209 3,476,421 -0.21 1.93 -13,886 6,696,282
2022-01-14 2022-01-12 4 IMRA IMARA Inc.
Common Stock 		S - Sale -4,634 3,483,630 -0.13 2.02 -9,357 7,034,494
2022-01-11 2022-01-11 4 IMRA IMARA Inc.
Common Stock 		S - Sale -2,409 3,488,264 -0.07 2.04 -4,919 7,123,384
2022-01-11 2022-01-10 4 IMRA IMARA Inc.
Common Stock 		S - Sale -1,751 3,490,673 -0.05 2.00 -3,502 6,981,346
2022-01-11 2022-01-07 4 IMRA IMARA Inc.
Common Stock 		S - Sale -14,600 3,492,424 -0.42 2.08 -30,318 7,252,368
2022-01-06 2022-01-06 4 IMRA IMARA Inc.
Common Stock 		S - Sale -10,257 3,507,024 -0.29 2.16 -22,205 7,592,356
2022-01-06 2022-01-05 4 IMRA IMARA Inc.
Common Stock 		S - Sale -8,200 3,517,281 -0.23 2.25 -18,439 7,909,310
2022-01-06 2022-01-04 4 IMRA IMARA Inc.
Common Stock 		S - Sale -13,459 3,525,481 -0.38 2.34 -31,544 8,262,670
2022-01-05 2022-01-03 4 BHG Bright Health Group Inc.
Series A Convertible Perpetual Preferred Stock 		P - Purchase 125,000 125,000 1,000.00 125,000,000 125,000,000
2022-01-05 2022-01-03 4 BHG Bright Health Group Inc.
Series A Convertible Perpetual Preferred Stock 		P - Purchase 75,000 75,000 1,000.00 75,000,000 75,000,000
2022-01-03 2022-01-03 4 IMRA IMARA Inc.
Common Stock 		S - Sale -44,665 3,538,940 -1.25 2.34 -104,396 8,271,564
2022-01-03 2021-12-31 4 IMRA IMARA Inc.
Common Stock 		S - Sale -49,953 3,583,605 -1.37 2.25 -112,409 8,064,186
2022-01-03 2021-12-30 4 IMRA IMARA Inc.
Common Stock 		S - Sale -21,858 3,633,558 -0.60 2.29 -50,066 8,322,665
2021-12-29 2021-12-29 4 IMRA IMARA Inc.
Common Stock 		S - Sale -15,196 3,655,416 -0.41 2.30 -34,954 8,408,188
2021-12-29 2021-12-28 4 IMRA IMARA Inc.
Common Stock 		S - Sale -24,580 3,670,612 -0.67 2.34 -57,539 8,592,536
2021-12-29 2021-12-27 4 IMRA IMARA Inc.
Common Stock 		S - Sale -27,651 3,695,192 -0.74 2.42 -67,007 8,954,559
2021-12-27 2021-12-23 4 IMRA IMARA Inc.
Common Stock 		S - Sale -23,961 3,722,843 -0.64 2.41 -57,746 8,972,052
2021-12-27 2021-12-22 4 IMRA IMARA Inc.
Common Stock 		S - Sale -20,109 3,746,804 -0.53 2.32 -46,679 8,697,456
2021-12-27 2021-12-21 4 IMRA IMARA Inc.
Common Stock 		S - Sale -41,222 3,766,913 -1.08 2.32 -95,804 8,754,683
2021-12-27 2021-12-20 4 IMRA IMARA Inc.
Common Stock 		S - Sale -38,123 3,808,135 -0.99 2.33 -88,720 8,862,292
2021-12-27 2021-12-20 4 IMRA IMARA Inc.
Common Stock 		S - Sale -47,000 3,846,258 -1.21 2.21 -103,884 8,501,384
2021-12-27 2021-12-16 4 IMRA IMARA Inc.
Common Stock 		S - Sale -44,993 3,893,258 -1.14 2.23 -100,546 8,700,264
2021-12-27 2021-12-15 4 IMRA IMARA Inc.
Common Stock 		S - Sale -28,817 3,938,251 -0.73 2.28 -65,685 8,976,849
2021-12-27 2021-12-14 4 IMRA IMARA Inc.
Common Stock 		S - Sale -15,093 3,967,068 -0.38 2.56 -38,643 10,156,884
2021-12-27 2021-12-13 4 IMRA IMARA Inc.
Common Stock 		S - Sale -17,501 3,982,161 -0.44 2.83 -49,558 11,276,285
2021-12-27 2021-12-10 4 IMRA IMARA Inc.
Common Stock 		S - Sale -8,667 3,999,662 -0.22 2.83 -24,541 11,325,443
2021-12-27 2021-12-09 4 IMRA IMARA Inc.
Common Stock 		S - Sale -5,666 4,008,329 -0.14 2.95 -16,693 11,809,339
2021-12-27 2021-12-22 4 MTCR Metacrine, Inc.
Common Stock 		S - Sale -170,932 2,563,257 -6.25 0.91 -155,565 2,332,820
2021-12-27 2021-12-22 4 MTCR Metacrine, Inc.
Common Stock 		S - Sale -288,768 2,734,189 -9.55 1.00 -289,288 2,739,111
2021-12-27 2021-12-10 4 MTCR Metacrine, Inc.
Common Stock 		S - Sale -37,570 3,022,957 -1.23 1.32 -49,630 3,993,326
2021-11-12 2021-11-10 4 HOOD Robinhood Markets, Inc.
Class A Common Stock 		J - Other 10,872 21,744 100.00
2021-11-12 2021-11-10 4 HOOD Robinhood Markets, Inc.
Class A Common Stock 		J - Other 10,872 21,744 100.00
2021-11-12 2021-11-10 4 HOOD Robinhood Markets, Inc.
Class A Common Stock 		J - Other -724,800 6,086,208 -10.64
2021-11-12 2021-11-10 4 HOOD Robinhood Markets, Inc.
Class A Common Stock 		J - Other -724,800 6,086,208 -10.64
2021-10-29 2021-10-27 4 HOOD Robinhood Markets, Inc.
Class A Common Stock 		J - Other 10,872 10,872
2021-10-29 2021-10-27 4 HOOD Robinhood Markets, Inc.
Class A Common Stock 		J - Other 10,872 10,872
2021-10-29 2021-10-27 4 HOOD Robinhood Markets, Inc.
Class A Common Stock 		J - Other -724,800 6,811,008 -9.62
2021-10-29 2021-10-27 4 HOOD Robinhood Markets, Inc.
Class A Common Stock 		J - Other -724,800 6,811,008 -9.62
2021-10-19 2021-10-18 4 TRVI Trevi Therapeutics, Inc.
3.5-Year Common Stock Warrant 		P - Purchase 1,851,852 1,851,852
2021-10-19 2021-10-18 4 TRVI Trevi Therapeutics, Inc.
7-Year Common Stock Warrant 		P - Purchase 1,851,852 1,851,852
2021-10-19 2021-10-18 4 TRVI Trevi Therapeutics, Inc.
Common Stock 		P - Purchase 1,851,852 7,789,850 31.19
2021-10-04 3 IONQ IonQ, Inc.
Common Stock 		29,229,659
2021-08-03 2021-08-02 4 HOOD Robinhood Markets, Inc.
Tranche I Convertible Promissory Note 		C - Conversion -1,449,600 0 -100.00
2021-08-03 2021-08-02 4 HOOD Robinhood Markets, Inc.
Tranche I Convertible Promissory Note 		C - Conversion -1,449,600 0 -100.00
2021-08-03 2021-08-02 4 HOOD Robinhood Markets, Inc.
Series F Redeemable Convertible Preferred Stock 		C - Conversion -1,600,000 0 -100.00
2021-08-03 2021-08-02 4 HOOD Robinhood Markets, Inc.
Series E Redeemable Convertible Preferred Stock 		C - Conversion -4,486,208 0 -100.00
2021-08-03 2021-08-02 4 HOOD Robinhood Markets, Inc.
Series E Redeemable Convertible Preferred Stock 		C - Conversion -1,521,305 0 -100.00
2021-08-03 2021-08-02 4 HOOD Robinhood Markets, Inc.
Series D Redeemable Convertible Preferred Stock 		C - Conversion -492,853 0 -100.00
2021-08-03 2021-08-02 4 HOOD Robinhood Markets, Inc.
Series C Redeemable Convertible Preferred Stock 		C - Conversion -5,804,240 0 -100.00
2021-08-03 2021-08-02 4 HOOD Robinhood Markets, Inc.
Series B Redeemable Convertible Preferred Stock 		C - Conversion -55,055,000 0 -100.00
2021-08-03 2021-08-02 4 HOOD Robinhood Markets, Inc.
Class A Common Stock 		C - Conversion 1,449,600 7,535,808 23.82 26.60 38,559,360 200,452,493
2021-08-03 2021-08-02 4 HOOD Robinhood Markets, Inc.
Class A Common Stock 		C - Conversion 1,449,600 7,535,808 23.82 26.60 38,559,360 200,452,493
2021-08-03 2021-08-02 4 HOOD Robinhood Markets, Inc.
Class A Common Stock 		J - Other 6,086,208 6,086,208
2021-08-03 2021-08-02 4 HOOD Robinhood Markets, Inc.
Class A Common Stock 		J - Other 65,382,518 65,382,518
2021-08-03 2021-08-02 4 HOOD Robinhood Markets, Inc.
Common Stock 		J - Other -6,086,208 0 -100.00
2021-08-03 2021-08-02 4 HOOD Robinhood Markets, Inc.
Common Stock 		J - Other -65,382,518 0 -100.00
2021-08-03 2021-08-02 4 HOOD Robinhood Markets, Inc.
Common Stock 		C - Conversion 1,600,000 6,086,208 35.66
2021-08-03 2021-08-02 4 HOOD Robinhood Markets, Inc.
Common Stock 		C - Conversion 4,486,208 4,486,208
2021-08-03 2021-08-02 4 HOOD Robinhood Markets, Inc.
Common Stock 		C - Conversion 1,521,305 65,382,518 2.38
2021-08-03 2021-08-02 4 HOOD Robinhood Markets, Inc.
Common Stock 		C - Conversion 492,853 63,861,213 0.78
2021-08-03 2021-08-02 4 HOOD Robinhood Markets, Inc.
Common Stock 		C - Conversion 5,804,240 63,368,360 10.08
2021-08-03 2021-08-02 4 HOOD Robinhood Markets, Inc.
Common Stock 		C - Conversion 55,055,000 57,564,120 2,194.20
2021-07-30 3 BGRY Berkshire Grey, Inc.
Class A Common Stock 		38,183,023
2021-07-29 3 HOOD Robinhood Markets, Inc.
Common Stock 		2,509,120
2021-06-30 2021-06-28 4 GLUE Monte Rosa Therapeutics, Inc.
Series C convertible preferred Stock 		C - Conversion -2,361,912 0 -100.00
2021-06-30 2021-06-28 4 GLUE Monte Rosa Therapeutics, Inc.
Series B convertible preferred stock 		C - Conversion -11,500,000 0 -100.00
2021-06-30 2021-06-28 4 GLUE Monte Rosa Therapeutics, Inc.
Series A-2 convertible preferred stock 		C - Conversion -9,588,725 0 -100.00
2021-06-30 2021-06-28 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock 		P - Purchase 1,050,000 7,692,298 15.81 19.00 19,950,000 146,153,662
2021-06-30 2021-06-28 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock 		C - Conversion 669,002 6,642,298 11.20
2021-06-30 2021-06-28 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock 		C - Conversion 3,257,328 5,973,296 119.93
2021-06-30 2021-06-28 4 GLUE Monte Rosa Therapeutics, Inc.
Common Stock 		C - Conversion 2,715,968 2,715,968
2021-06-30 2021-06-28 4 BHG Bright Health Group Inc.
Series E Preferred 		C - Conversion -2,448,856 0 -100.00
2021-06-30 2021-06-28 4 BHG Bright Health Group Inc.
Series E Preferred 		C - Conversion -1,224,428 0 -100.00
2021-06-30 2021-06-28 4 BHG Bright Health Group Inc.
Series D Preferred 		C - Conversion -4,980,687 0 -100.00
2021-06-30 2021-06-28 4 BHG Bright Health Group Inc.
Series D Preferred 		C - Conversion -12,712,399 0 -100.00
2021-06-30 2021-06-28 4 BHG Bright Health Group Inc.
Series D Preferred 		C - Conversion -1,164,748 0 -100.00
2021-06-30 2021-06-28 4 BHG Bright Health Group Inc.
Series D Preferred 		C - Conversion -1,109,284 0 -100.00
2021-06-30 2021-06-28 4 BHG Bright Health Group Inc.
Series C Preferred 		C - Conversion -1,954,906 0 -100.00
2021-06-30 2021-06-28 4 BHG Bright Health Group Inc.
Series C Preferred 		C - Conversion -6,516,356 0 -100.00
2021-06-30 2021-06-28 4 BHG Bright Health Group Inc.
Series B Preferred 		C - Conversion -8,901,166 0 -100.00
2021-06-30 2021-06-28 4 BHG Bright Health Group Inc.
Series A Preferred 		C - Conversion -15,619,807 0 -100.00
2021-06-30 2021-06-28 4 BHG Bright Health Group Inc.
Common Stock 		P - Purchase 1,694,444 23,983,073 7.60 18.00 30,499,992 431,695,314
2021-06-30 2021-06-28 4 BHG Bright Health Group Inc.
Common Stock 		C - Conversion 7,346,568 22,288,629 49.17
2021-06-30 2021-06-28 4 BHG Bright Health Group Inc.
Common Stock 		C - Conversion 14,942,061 14,942,061
2021-06-30 2021-06-28 4 BHG Bright Health Group Inc.
Common Stock 		P - Purchase 250,000 47,925,199 0.52 18.00 4,500,000 862,653,582
2021-06-30 2021-06-28 4 BHG Bright Health Group Inc.
Common Stock 		C - Conversion 3,673,284 47,675,199 8.35
2021-06-30 2021-06-28 4 BHG Bright Health Group Inc.
Common Stock 		C - Conversion 38,137,197 44,001,915 650.28
2021-06-30 2021-06-28 4 BHG Bright Health Group Inc.
Common Stock 		C - Conversion 5,864,718 5,864,718
2021-06-30 2021-06-28 4 BHG Bright Health Group Inc.
Common Stock 		C - Conversion 3,494,244 3,494,244
2021-06-30 2021-06-28 4 BHG Bright Health Group Inc.
Common Stock 		C - Conversion 3,327,852 107,041,764 3.21
2021-06-30 2021-06-28 4 BHG Bright Health Group Inc.
Common Stock 		C - Conversion 19,549,068 103,713,912 23.23
2021-06-30 2021-06-28 4 BHG Bright Health Group Inc.
Common Stock 		C - Conversion 26,703,498 84,164,844 46.47
2021-06-30 2021-06-28 4 BHG Bright Health Group Inc.
Common Stock 		C - Conversion 10,601,925 57,461,346 22.62
2021-06-24 3 BHG Bright Health Group Inc.
Common Stock 		46,859,421
2021-06-10 2021-06-08 4 DM Desktop Metal, Inc.
Class A Common Stock 		J - Other 54 54
2021-06-10 2021-06-08 4 DM Desktop Metal, Inc.
Class A Common Stock 		J - Other 54 54
2021-06-10 2021-06-08 4 DM Desktop Metal, Inc.
Class A Common Stock 		J - Other 54 54
2021-06-10 2021-06-08 4 DM Desktop Metal, Inc.
Class A Common Stock 		J - Other 3,531 3,531
2021-06-10 2021-06-08 4 DM Desktop Metal, Inc.
Class A Common Stock 		J - Other -135,000 0 -100.00
2021-06-10 2021-06-08 4 DM Desktop Metal, Inc.
Class A Common Stock 		J - Other 135,000 135,000
2021-06-10 2021-06-08 4 DM Desktop Metal, Inc.
Class A Common Stock 		J - Other -9,000,000 19,263,413 -31.84
2021-05-26 2021-05-24 4 EAR Eargo, Inc.
Common Stock 		J - Other 821 821
2021-05-26 2021-05-24 4 EAR Eargo, Inc.
Common Stock 		J - Other -30,000 0 -100.00
2021-05-26 2021-05-24 4 EAR Eargo, Inc.
Common Stock 		J - Other 30,000 30,000
2021-05-26 2021-05-24 4 EAR Eargo, Inc.
Common Stock 		J - Other -2,000,000 4,520,019 -30.67
2021-04-15 2021-04-13 4 RPHM Reneo Pharmaceuticals, Inc.
Series B Preferred Stock 		C - Conversion -8,904,280 0 -100.00
2021-04-15 2021-04-13 4 RPHM Reneo Pharmaceuticals, Inc.
Series A Preferred Stock 		C - Conversion -9,526,652 0 -100.00
2021-04-15 2021-04-13 4 RPHM Reneo Pharmaceuticals, Inc.
Common Stock 		P - Purchase 666,666 4,785,494 16.19 15.00 9,999,990 71,782,410
2021-04-15 2021-04-13 4 RPHM Reneo Pharmaceuticals, Inc.
Common Stock 		C - Conversion 1,989,872 4,118,828 93.47
2021-04-15 2021-04-13 4 RPHM Reneo Pharmaceuticals, Inc.
Common Stock 		C - Conversion 2,128,956 2,128,956
2021-03-18 2021-03-16 4 MRKR Marker Therapeutics, Inc.
Common Stock 		P - Purchase 5,714,285 10,714,285 114.29 1.75 9,999,999 18,749,999
2021-03-16 3 SVRA Savara Inc
Common Stock 		24,137,931
2021-01-04 3 VRNA Verona Pharma plc
Ordinary Shares 		9,757,393
2021-01-04 3 VRNA Verona Pharma plc
Ordinary Shares 		31,111,112
2020-12-11 3 DM Desktop Metal, Inc.
Class A Common Stock 		28,263,413
2020-12-11 3 DM Desktop Metal, Inc.
Class A Common Stock 		135,514
2020-12-07 2020-12-04 4 RGLS Regulus Therapeutics Inc.
Class A-3 Convertible Preferred Stock 		P - Purchase 258,707 258,707 6.22 1,609,158 1,609,158
2020-12-07 2020-12-04 4 RGLS Regulus Therapeutics Inc.
Common Stock Purchase Warrant (right to buy) 		P - Purchase 5,239,254 5,239,254 0.12 654,907 654,907
2020-12-07 2020-12-04 4 RGLS Regulus Therapeutics Inc.
Common Stock 		P - Purchase 4,398,602 6,451,056 214.31 0.62 2,735,930 4,012,557
2020-10-22 2020-10-20 4 EAR Eargo, Inc.
Series E Preferred Stock 		C - Conversion -1,433,459 0 -100.00
2020-10-22 2020-10-20 4 EAR Eargo, Inc.
Series D Preferred Stock 		C - Conversion -560,789 0 -100.00
2020-10-22 2020-10-20 4 EAR Eargo, Inc.
Series C-1 Preferred Stock 		C - Conversion -762,959 0 -100.00
2020-10-22 2020-10-20 4 EAR Eargo, Inc.
Series C Preferred Stock 		C - Conversion -1,274,929 0 -100.00
2020-10-22 2020-10-20 4 EAR Eargo, Inc.
Series B-1 Preferred Stock 		C - Conversion -546,532 0 -100.00
2020-10-22 2020-10-20 4 EAR Eargo, Inc.
Common Stock 		P - Purchase 311,111 6,520,017 5.01 18.00 5,599,998 117,360,306
2020-10-22 2020-10-20 4 EAR Eargo, Inc.
Common Stock 		C - Conversion 1,433,459 6,208,906 30.02
2020-10-22 2020-10-20 4 EAR Eargo, Inc.
Common Stock 		C - Conversion 699,163 4,775,447 17.15
2020-10-22 2020-10-20 4 EAR Eargo, Inc.
Common Stock 		C - Conversion 791,214 4,076,284 24.09
2020-10-22 2020-10-20 4 EAR Eargo, Inc.
Common Stock 		C - Conversion 1,426,354 3,285,070 76.74
2020-10-22 2020-10-20 4 EAR Eargo, Inc.
Common Stock 		C - Conversion 1,858,716 1,858,716
2020-09-22 2020-09-18 4 MTCR Metacrine, Inc.
Series C Convertible Preferred Stock 		C - Conversion -332,964 0 -100.00
2020-09-22 2020-09-18 4 MTCR Metacrine, Inc.
Series B Convertible Preferred Stock 		C - Conversion -1,958,333 0 -100.00
2020-09-22 2020-09-18 4 MTCR Metacrine, Inc.
Common Stock 		P - Purchase 769,230 3,060,527 33.57 13.00 9,999,990 39,786,851
2020-09-22 2020-09-18 4 MTCR Metacrine, Inc.
Common Stock 		C - Conversion 332,964 2,291,297 17.00
2020-09-22 2020-09-18 4 MTCR Metacrine, Inc.
Common Stock 		C - Conversion 1,958,333 1,958,333
2020-09-16 2020-09-14 4 MRSN Mersana Therapeutics, Inc.
Common Stock 		J - Other 248 745 49.90
2020-09-16 2020-09-14 4 MRSN Mersana Therapeutics, Inc.
Common Stock 		J - Other 596 596
2020-09-16 2020-09-14 4 MRSN Mersana Therapeutics, Inc.
Common Stock 		J - Other -10,000 0 -100.00
2020-09-16 2020-09-14 4 MRSN Mersana Therapeutics, Inc.
Common Stock 		J - Other 10,000 10,000
2020-09-16 2020-09-14 4 MRSN Mersana Therapeutics, Inc.
Common Stock 		J - Other -20,000 0 -100.00
2020-09-16 2020-09-14 4 MRSN Mersana Therapeutics, Inc.
Common Stock 		J - Other 20,000 20,000
2020-09-16 2020-09-14 4 MRSN Mersana Therapeutics, Inc.
Common Stock 		J - Other -2,000,000 5,959,520 -25.13
2020-09-16 2020-05-06 4 MRSN Mersana Therapeutics, Inc.
Common Stock 		G - Gift -1,146 0 -100.00
2020-07-28 2020-07-24 4 GNCA GENOCEA BIOSCIENCES, INC.
Warrant to Purchase Common Stock 		P - Purchase 3,151,260 3,151,260 0.13 409,664 409,664
2020-07-28 2020-07-24 4 GNCA GENOCEA BIOSCIENCES, INC.
Common Stock 		P - Purchase 3,151,260 10,376,936 43.61 2.25 7,090,335 23,348,106
2020-07-28 2020-07-28 4 INZY Inozyme Pharma, Inc.
Common Stock 		P - Purchase 250,000 2,437,689 11.43 16.00 4,000,000 39,003,024
2020-07-28 2020-07-28 4 INZY Inozyme Pharma, Inc.
Common Stock 		C - Conversion 187,156 2,187,689 9.36
2020-07-28 2020-07-28 4 INZY Inozyme Pharma, Inc.
Common Stock 		C - Conversion 2,000,533 2,000,533
2020-07-28 2020-07-25 4 INZY Inozyme Pharma, Inc.
Series A-2 Preferred Stock 		C - Conversion -187,156 0 -100.00
2020-07-28 2020-07-25 4 INZY Inozyme Pharma, Inc.
Series A Preferred Stock 		C - Conversion -2,000,533 0 -100.00
2020-07-16 2020-07-14 4 NKTK Nkarta, Inc.
Series B Preferred Stock 		C - Conversion -1,712,810 0 -100.00
2020-07-16 2020-07-14 4 NKTK Nkarta, Inc.
Series A Preferred Stock 		C - Conversion -522,639 0 -100.00
2020-07-16 2020-07-14 4 NKTK Nkarta, Inc.
Common Stock 		P - Purchase 666,666 2,902,115 29.82 18.00 11,999,988 52,238,070
2020-07-16 2020-07-14 4 NKTK Nkarta, Inc.
Common Stock 		C - Conversion 1,712,810 2,235,449 327.72
2020-07-16 2020-07-14 4 NKTK Nkarta, Inc.
Common Stock 		C - Conversion 522,639 522,639
2020-07-01 2020-06-30 4 AKUS Akouos, Inc.
Series B Preferred Stock 		C - Conversion -1,199,976 0 -100.00
2020-07-01 2020-06-30 4 AKUS Akouos, Inc.
Series A Preferred Stock 		C - Conversion -1,992,238 0 -100.00
2020-07-01 2020-06-30 4 AKUS Akouos, Inc.
Series Seed Preferred Stock 		C - Conversion -513,758 0 -100.00
2020-07-01 2020-06-30 4 AKUS Akouos, Inc.
Common Stock 		P - Purchase 588,235 4,294,207 15.87 17.00 9,999,995 73,001,519
2020-07-01 2020-06-30 4 AKUS Akouos, Inc.
Common Stock 		C - Conversion 1,199,976 3,705,972 47.88
2020-07-01 2020-06-30 4 AKUS Akouos, Inc.
Common Stock 		C - Conversion 1,992,238 2,505,996 387.78
2020-07-01 2020-06-30 4 AKUS Akouos, Inc.
Common Stock 		C - Conversion 513,758 513,758
2020-06-22 2020-06-19 4 AVEO AVEO PHARMACEUTICALS, INC.
Common Stock 		P - Purchase 1,428,571 3,952,958 56.59 5.25 7,499,998 20,753,030
2020-05-22 2020-05-20 4 SURF Surface Oncology, Inc.
Common Stock 		S - Sale -420,000 2,892,877 -12.68 3.66 -1,535,562 10,576,648
2020-04-13 2019-08-28 4 MRSN Mersana Therapeutics, Inc.
Stock Purchase Warrant (right to buy) 		X - Other -70,593 0 -100.00
2020-04-13 2019-08-28 4 MRSN Mersana Therapeutics, Inc.
Common Stock 		S - Sale -1,211 11,959,520 -0.01 2.91 -3,524 34,802,203
2020-04-13 2019-08-28 4 MRSN Mersana Therapeutics, Inc.
Common Stock 		X - Other 70,593 11,960,731 0.59 0.05 3,530 598,037
2020-04-13 2020-04-03 4 TRVI Trevi Therapeutics, Inc.
Call Option (right to buy) 		X - Other -1,500,000 0 -100.00
2020-04-13 2020-04-03 4 TRVI Trevi Therapeutics, Inc.
Common Stock 		S - Sale -564 5,937,998 -0.01 2.66 -1,500 15,795,075
2020-04-13 2020-04-03 4 TRVI Trevi Therapeutics, Inc.
Common Stock 		X - Other 1,500,000 5,938,562 33.79 0.00 1,500 5,939
2020-04-13 2020-04-09 4 MRSN Mersana Therapeutics, Inc.
Common Stock 		J - Other 497 497
2020-04-13 2020-04-09 4 MRSN Mersana Therapeutics, Inc.
Common Stock 		J - Other 1,146 1,146
2020-04-13 2020-04-09 4 MRSN Mersana Therapeutics, Inc.
Common Stock 		J - Other -20,000 0 -100.00
2020-04-13 2020-04-09 4 MRSN Mersana Therapeutics, Inc.
Common Stock 		J - Other 20,000 20,000
2020-04-13 2020-04-09 4 MRSN Mersana Therapeutics, Inc.
Common Stock 		J - Other -40,000 0 -100.00
2020-04-13 2020-04-09 4 MRSN Mersana Therapeutics, Inc.
Common Stock 		J - Other 40,000 40,000
2020-04-13 2020-04-09 4 MRSN Mersana Therapeutics, Inc.
Common Stock 		J - Other -4,000,000 7,959,520 -33.45
2020-03-16 2020-03-16 4 IMRA IMARA Inc.
Series B Preferred Stock 		C - Conversion -5,625,926 0 -100.00
2020-03-16 2020-03-16 4 IMRA IMARA Inc.
Series A Preferred Stock 		C - Conversion -15,323,454 0 -100.00
2020-03-16 2020-03-16 4 IMRA IMARA Inc.
Series Seed Preferred Stock 		C - Conversion -1,342,780 0 -100.00
2020-03-16 2020-03-16 4 IMRA IMARA Inc.
Common Stock 		P - Purchase 475,000 4,013,995 13.42 16.00 7,600,000 64,223,920
2020-03-16 2020-03-16 4 IMRA IMARA Inc.
Common Stock 		C - Conversion 3,538,995 3,538,995
2020-03-10 2020-03-06 4 CSBR CHAMPIONS ONCOLOGY, INC.
Warrant to Purchase Common Stock (right to buy) 		X - Other -859,375 0 -100.00
2020-03-10 2020-03-06 4 CSBR CHAMPIONS ONCOLOGY, INC.
Common Stock 		S - Sale -708,155 1,713,720 -29.24 6.99 -4,950,003 11,978,903
2020-03-10 2020-03-06 4 CSBR CHAMPIONS ONCOLOGY, INC.
Common Stock 		X - Other 859,375 2,421,875 55.00 5.76 4,950,000 13,950,000
2020-02-12 2020-02-10 4 CSPR Casper Sleep Inc.
Common Stock 		P - Purchase 1,250,000 6,222,412 25.14 12.00 15,000,000 74,668,944
2020-02-06 3 CSPR Casper Sleep Inc.
Common Stock 		9,944,824
2020-02-06 3 CSPR Casper Sleep Inc.
Common Stock 		9,944,824
2020-02-06 3 CSPR Casper Sleep Inc.
Common Stock 		9,944,824
2020-02-06 3 CSPR Casper Sleep Inc.
Common Stock 		9,944,824
2020-02-06 3 CSPR Casper Sleep Inc.
Common Stock 		9,944,824
2020-02-06 3 CSPR Casper Sleep Inc.
Common Stock 		9,944,824
2020-02-06 3 CSPR Casper Sleep Inc.
Common Stock 		9,944,824
2020-02-06 3 CSPR Casper Sleep Inc.
Common Stock 		9,944,824
2020-02-06 3 CSPR Casper Sleep Inc.
Common Stock 		9,944,824
2020-02-06 3 CSPR Casper Sleep Inc.
Common Stock 		9,944,824
2020-01-28 2020-01-24 4 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share 		P - Purchase 7,500,000 19,500,000 62.50 0.67 5,000,250 13,000,650
2019-12-26 2019-12-24 4 RGLS Regulus Therapeutics Inc.
Class A-2 Convertible Preferred Stock 		P - Purchase 900,900 900,900 6.66 5,999,994 5,999,994
2019-12-26 2019-12-24 4 RGLS Regulus Therapeutics Inc.
Common Stock Purchase Warrant (Right to Buy) 		P - Purchase 9,009,000 9,009,000 0.12 1,126,125 1,126,125
2019-12-09 2019-12-09 4 ARDX ARDELYX, INC.
Common Stock 		A - Award 400,000 3,482,186 12.98 6.25 2,500,000 21,763,662
2019-11-12 2019-11-12 4 GRTX Galera Therapeutics, Inc.
Series C Preferred Stock 		C - Conversion -1,354,829 0 -100.00
2019-11-12 2019-11-12 4 GRTX Galera Therapeutics, Inc.
Series B Preferred Stock 		C - Conversion -9,600,000 0 -100.00
2019-11-12 2019-11-12 4 GRTX Galera Therapeutics, Inc.
Series A Preferred Stock 		C - Conversion -8,975,000 0 -100.00
2019-11-12 2019-11-12 4 GRTX Galera Therapeutics, Inc.
Common Stock 		P - Purchase 416,666 4,358,047 10.57 12.00 4,999,992 52,296,564
2019-11-12 2019-11-12 4 GRTX Galera Therapeutics, Inc.
Common Stock 		C - Conversion 267,935 3,941,381 7.29
2019-11-12 2019-11-12 4 GRTX Galera Therapeutics, Inc.
Common Stock 		C - Conversion 1,898,524 3,673,446 106.96
2019-11-12 2019-11-12 4 GRTX Galera Therapeutics, Inc.
Common Stock 		C - Conversion 1,774,922 1,774,922
2019-11-04 2019-11-04 4 OYST Oyster Point Pharma, Inc.
Series B Convertible Preferred Stock 		C - Conversion -1,061,547 0 -100.00
2019-11-04 2019-11-04 4 OYST Oyster Point Pharma, Inc.
Series A Convertible Preferred Stock 		C - Conversion -3,606,282 0 -100.00
2019-11-04 2019-11-04 4 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share 		P - Purchase 935,000 5,925,287 18.74 16.00 14,960,000 94,804,592
2019-11-04 2019-11-04 4 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share 		C - Conversion 1,061,547 4,990,287 27.02
2019-11-04 2019-11-04 4 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share 		C - Conversion 3,606,282 3,928,740 1,118.37
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share 		644,916
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share 		644,916
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share 		644,916
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share 		644,916
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share 		644,916
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share 		644,916
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share 		644,916
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share 		644,916
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share 		644,916
2019-10-30 3 OYST Oyster Point Pharma, Inc.
Common Stock, par value $0.001 per share 		644,916
2019-07-24 2019-07-22 4 MIRM Mirum Pharmaceuticals, Inc.
Series A Preferred Stock 		C - Conversion -29,889,945 0 -100.00
2019-07-24 2019-07-22 4 MIRM Mirum Pharmaceuticals, Inc.
Common Stock 		P - Purchase 450,000 4,186,243 12.04 15.00 6,750,000 62,793,645
2019-07-24 2019-07-22 4 MIRM Mirum Pharmaceuticals, Inc.
Common Stock 		C - Conversion 3,736,243 3,736,243
2019-06-25 2019-06-24 4 GNCA GENOCEA BIOSCIENCES, INC.
Common Stock 		P - Purchase 2,857,142 7,225,676 65.40 3.50 9,999,997 25,289,866
2019-06-07 2019-06-07 4 NITE Nightstar Therapeutics plc
Ordinary Shares 		D - Sale to Issuer -6,662,532 0 -100.00 25.50 -169,894,566
2019-05-13 2019-05-09 4 TRVI Trevi Therapeutics, Inc.
Series C Preferred Stock 		C - Conversion -17,099,315 0 -100.00
2019-05-13 2019-05-09 4 TRVI Trevi Therapeutics, Inc.
Common Stock 		P - Purchase 1,500,000 4,438,562 51.05 10.00 15,000,000 44,385,620
2019-05-13 2019-05-09 4 TRVI Trevi Therapeutics, Inc.
Common Stock 		P - Purchase 1,000,000 2,938,562 51.58 10.00 10,000,000 29,385,620
2019-05-13 2019-05-09 4 TRVI Trevi Therapeutics, Inc.
Common Stock 		C - Conversion 1,938,562 1,938,562
2019-05-09 2019-05-07 4 RGLS Regulus Therapeutics Inc.
Class A-1 Convertible Preferred Stock 		P - Purchase 256,700 256,700 10.80 2,772,360 2,772,360
2019-05-09 2019-05-07 4 RGLS Regulus Therapeutics Inc.
Common Stock Purchase Warrant (Right to Buy) 		P - Purchase 3,703,704 3,703,704 0.12 462,963 462,963
2019-05-09 2019-05-07 4 RGLS Regulus Therapeutics Inc.
Common Stock 		P - Purchase 1,136,704 2,052,454 124.13 1.08 1,227,640 2,216,650
2019-04-08 2019-04-08 4 AVEO AVEO PHARMACEUTICALS INC
Warrant to Purchase Common Stock 		P - Purchase 4,347,827 4,347,827 0.01 43,478 43,478
2019-04-08 2019-04-08 4 AVEO AVEO PHARMACEUTICALS INC
Common Stock 		P - Purchase 4,347,827 25,243,865 20.81 1.14 4,956,523 28,778,006
2019-03-06 2019-03-05 4 MRSN Mersana Therapeutics, Inc.
Common Stock 		P - Purchase 3,750,000 11,890,138 46.07 4.00 15,000,000 47,560,552
2019-02-19 2019-02-14 4 GNCA GENOCEA BIOSCIENCES, INC.
Warrant to Purchase Common Stock 		P - Purchase 2,487,067 2,487,067 0.12 310,883 310,883
2019-02-19 2019-02-14 4 GNCA GENOCEA BIOSCIENCES, INC.
Common Stock 		P - Purchase 9,948,269 34,948,269 39.79 0.47 4,688,619 16,471,119
2019-01-02 3 NITE Nightstar Therapeutics plc
Ordinary Shares 		13,325,064
2019-01-02 3 NITE Nightstar Therapeutics plc
Ordinary Shares 		13,325,064
2019-01-02 3 NITE Nightstar Therapeutics plc
Ordinary Shares 		13,325,064
2019-01-02 3 NITE Nightstar Therapeutics plc
Ordinary Shares 		13,325,064
2019-01-02 3 NITE Nightstar Therapeutics plc
Ordinary Shares 		13,325,064
2019-01-02 3 NITE Nightstar Therapeutics plc
Ordinary Shares 		13,325,064
2019-01-02 3 NITE Nightstar Therapeutics plc
Ordinary Shares 		13,325,064
2019-01-02 3 NITE Nightstar Therapeutics plc
Ordinary Shares 		13,325,064
2019-01-02 3 NITE Nightstar Therapeutics plc
Ordinary Shares 		13,325,064
2019-01-02 3 NITE Nightstar Therapeutics plc
Ordinary Shares 		13,325,064
2019-01-02 3 NITE Nightstar Therapeutics plc
Ordinary Shares 		13,325,064
2019-01-02 3 NITE Nightstar Therapeutics plc
Ordinary Shares 		13,325,064
2018-12-21 2018-12-21 4 AVEO AVEO PHARMACEUTICALS INC
Common Stock 		P - Purchase 300,000 20,896,038 1.46 1.49 448,380 31,231,218
2018-12-21 2018-12-20 4 AVEO AVEO PHARMACEUTICALS INC
Common Stock 		P - Purchase 200,000 20,596,038 0.98 1.63 326,060 33,577,721
2018-12-12 2018-12-11 4 AVEO AVEO PHARMACEUTICALS INC
Common Stock 		P - Purchase 61,200 20,396,038 0.30 1.98 121,084 40,353,561
2018-12-11 3 MLND Millendo Therapeutics, Inc.
Common Stock 		3,532,814
2018-12-11 3 MLND Millendo Therapeutics, Inc.
Common Stock 		3,532,814
2018-12-11 3 MLND Millendo Therapeutics, Inc.
Common Stock 		3,532,814
2018-12-10 2018-12-10 4 AVEO AVEO PHARMACEUTICALS INC
Common Stock 		P - Purchase 26,000 20,334,838 0.13 1.98 51,576 40,338,218
2018-12-10 2018-12-07 4 AVEO AVEO PHARMACEUTICALS INC
Common Stock 		P - Purchase 117,100 20,308,838 0.58 1.98 232,362 40,298,827
2018-12-10 2018-12-06 4 AVEO AVEO PHARMACEUTICALS INC
Common Stock 		P - Purchase 27,300 20,191,738 0.14 1.99 54,414 40,246,172
2018-11-30 2018-11-30 4 AVEO AVEO PHARMACEUTICALS INC
Common Stock 		P - Purchase 71,900 20,164,438 0.36 1.98 142,067 39,842,913
2018-11-30 2018-11-28 4 AVEO AVEO PHARMACEUTICALS INC
Common Stock 		P - Purchase 24,500 20,092,538 0.12 1.99 48,824 40,040,410
2018-11-21 2018-11-20 4 AVEO AVEO PHARMACEUTICALS INC
Common Stock 		P - Purchase 170,000 20,068,038 0.85 1.98 336,107 39,676,518
2018-11-19 2018-11-19 4 AVEO AVEO PHARMACEUTICALS INC
Common Stock 		P - Purchase 510,000 19,898,038 2.63 1.88 956,658 37,324,740
2018-11-19 2018-11-16 4 AVEO AVEO PHARMACEUTICALS INC
Common Stock 		P - Purchase 350,000 19,388,038 1.84 1.86 649,355 35,970,627
2018-11-19 2018-11-15 4 AVEO AVEO PHARMACEUTICALS INC
Common Stock 		P - Purchase 340,000 19,038,038 1.82 1.86 631,958 35,386,001
2018-10-18 3 MRKR Marker Therapeutics, Inc.
Common Stock 		10,000,000
2018-10-18 3 MRKR Marker Therapeutics, Inc.
Common Stock 		10,000,000
2018-10-18 3 MRKR Marker Therapeutics, Inc.
Common Stock 		10,000,000
2018-09-10 2018-09-07 4 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share 		P - Purchase 12,000,000 12,000,000 1.67 20,000,400 20,000,400
2018-09-10 2018-09-07 4 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share 		P - Purchase 3,000,000 82,978,668 3.75 1.67 5,000,100 138,300,546
2018-08-22 2018-08-21 4 AVEO AVEO PHARMACEUTICALS INC
Common Stock 		P - Purchase 663,716 18,698,038 3.68 2.26 1,499,998 42,257,566
2018-07-20 2018-07-19 4 AVEO AVEO PHARMACEUTICALS INC
Common Stock 		P - Purchase 50,600 18,034,322 0.28 2.00 101,165 36,056,020
2018-07-20 2018-07-18 4 AVEO AVEO PHARMACEUTICALS INC
Common Stock 		P - Purchase 200,000 17,983,722 1.12 1.95 390,580 35,120,411
2018-06-28 2018-06-28 4 AVEO AVEO PHARMACEUTICALS INC
Common Stock 		P - Purchase 187,130 17,783,722 1.06 2.10 392,692 37,319,141
2018-06-28 2018-06-27 4 AVEO AVEO PHARMACEUTICALS INC
Common Stock 		P - Purchase 5,295 17,596,592 0.03 2.15 11,384 37,832,673
2018-05-30 2018-05-30 4 AVEO AVEO PHARMACEUTICALS INC
Common Stock 		P - Purchase 275 17,591,297 0.00 2.15 591 37,821,289
2018-05-30 2018-05-25 4 ARDX ARDELYX, INC.
Common Stock 		A - Award 416,667 3,082,186 15.63 4.00 1,666,668 12,328,744
2018-05-30 2018-05-25 4 ARDX ARDELYX, INC.
Common Stock 		A - Award 416,666 3,082,186 15.63 4.00 1,666,664 12,328,744
2018-05-21 2018-05-21 4 AVEO AVEO PHARMACEUTICALS INC
Common Stock 		P - Purchase 32,200 17,591,022 0.18 2.14 69,059 37,727,465
2018-05-21 2018-05-18 4 AVEO AVEO PHARMACEUTICALS INC
Common Stock 		P - Purchase 20,100 17,558,822 0.11 2.14 42,928 37,500,376
2018-05-21 2018-05-17 4 AVEO AVEO PHARMACEUTICALS INC
Common Stock 		P - Purchase 184,179 17,538,722 1.06 2.13 391,436 37,275,046
2018-05-10 2018-05-08 4 AVEO AVEO PHARMACEUTICALS INC
Common Stock 		P - Purchase 70,873 17,354,543 0.41 2.13 151,250 37,036,330
2018-05-09 2018-05-01 4 MULE MULESOFT, INC
Class B Common Stock 		C - Conversion -858,978 0 -100.00
2018-05-09 2018-05-01 4 MULE MULESOFT, INC
Class B Common Stock 		C - Conversion -2,576,939 0 -100.00
2018-05-09 2018-05-01 4 MULE MULESOFT, INC
Class B Common Stock 		C - Conversion -12,679,970 0 -100.00
2018-05-09 2018-05-01 4 MULE MULESOFT, INC
Class A Common Stock 		U - Other -858,978 0 -100.00
2018-05-09 2018-05-01 4 MULE MULESOFT, INC
Class A Common Stock 		C - Conversion 858,978 858,978
2018-05-09 2018-05-01 4 MULE MULESOFT, INC
Class A Common Stock 		U - Other -2,576,939 0 -100.00
2018-05-09 2018-05-01 4 MULE MULESOFT, INC
Class A Common Stock 		C - Conversion 2,576,939 2,576,939
2018-05-09 2018-05-01 4 MULE MULESOFT, INC
Class A Common Stock 		U - Other -12,679,970 0 -100.00
2018-05-09 2018-05-01 4 MULE MULESOFT, INC
Class A Common Stock 		C - Conversion 12,679,970 12,679,970
2018-04-23 2018-04-23 4 SURF Surface Oncology, Inc.
Series A Preferred Stock 		C - Conversion -6,995,000 0 -100.00
2018-04-23 2018-04-23 4 SURF Surface Oncology, Inc.
Common Stock 		P - Purchase 133,333 3,312,877 4.19 15.00 1,999,995 49,693,155
2018-04-23 2018-04-23 4 SURF Surface Oncology, Inc.
Common Stock 		C - Conversion 3,179,544 3,179,544
2018-04-10 2018-04-10 4 AVEO AVEO PHARMACEUTICALS INC
Common Stock 		P - Purchase 203,200 17,283,670 1.19 2.46 499,994 42,528,198
2018-04-10 2018-04-09 4 AVEO AVEO PHARMACEUTICALS INC
Common Stock 		P - Purchase 32,100 17,080,470 0.19 2.43 78,099 41,556,784
2018-04-10 2018-04-06 4 AVEO AVEO PHARMACEUTICALS INC
Common Stock 		P - Purchase 685,676 17,048,370 4.19 2.24 1,536,943 38,213,921
2018-03-28 2018-03-27 4 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share 		P - Purchase 6,000,000 79,978,672 8.11 1.92 11,500,200 153,295,121
2018-03-28 2018-03-26 4 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share 		P - Purchase 571,164 73,978,672 0.78 1.90 1,087,553 140,862,789
2018-03-27 2018-03-27 4 TCON Tracon Pharmaceuticals, Inc.
Warrant to Purchase Common Stock 		P - Purchase 707,964 707,964 0.12 88,496 88,496
2018-03-27 2018-03-27 4 TCON Tracon Pharmaceuticals, Inc.
Common Stock 		P - Purchase 707,964 3,466,003 25.67 2.70 1,911,503 9,358,208
2018-03-23 2018-03-23 4 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share 		P - Purchase 294,090 73,407,508 0.40 1.95 572,358 142,865,692
2018-03-23 2018-03-22 4 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share 		P - Purchase 869,574 73,113,418 1.20 1.90 1,655,669 139,207,948
2018-03-23 2018-03-21 4 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share 		P - Purchase 104,844 72,243,844 0.15 1.81 189,820 130,797,480
2018-03-13 2018-03-09 4 CASC Cascadian Therapeutics, Inc.
Common Stock 		U - Other -10,882,574 0 -100.00
2018-02-27 2018-02-26 4 ABIO ARCA biopharma, Inc.
Common Stock 		S - Sale -1,460,209 0 -100.00 0.50 -731,273
2018-02-22 2018-02-20 4 CASC Cascadian Therapeutics, Inc.
Series E Preferred Stock 		C - Conversion -1,818,000 0 -100.00
2018-02-22 2018-02-20 4 CASC Cascadian Therapeutics, Inc.
Common Stock 		C - Conversion 1,818,000 10,882,574 20.06 3.30 5,999,400 35,912,494
2018-02-15 2018-02-13 4 APPN APPIAN CORP
Class B Common Stock 		C - Conversion -2,724,202 0 -100.00
2018-02-15 2018-02-13 4 APPN APPIAN CORP
Class A Common Stock 		J - Other 339 339
2018-02-15 2018-02-13 4 APPN APPIAN CORP
Class A Common Stock 		J - Other 676 676
2018-02-15 2018-02-13 4 APPN APPIAN CORP
Class A Common Stock 		J - Other -13,621 0 -100.00
2018-02-15 2018-02-13 4 APPN APPIAN CORP
Class A Common Stock 		J - Other 13,621 13,621
2018-02-15 2018-02-13 4 APPN APPIAN CORP
Class A Common Stock 		J - Other -27,242 0 -100.00
2018-02-15 2018-02-13 4 APPN APPIAN CORP
Class A Common Stock 		J - Other 27,242 27,242
2018-02-15 2018-02-13 4 APPN APPIAN CORP
Class A Common Stock 		J - Other -2,724,202 0 -100.00
2018-02-15 2018-02-13 4 APPN APPIAN CORP
Class A Common Stock 		C - Conversion 2,724,202 2,724,202
2018-01-26 2018-01-26 4 SYBX SYNLOGIC, INC.
Common Stock 		A - Award 410,000 4,228,940 10.74 9.75 3,997,500 41,232,165
2018-01-23 3 GNCA GENOCEA BIOSCIENCES, INC.
Common Stock 		50,000,000
2018-01-23 3 GNCA GENOCEA BIOSCIENCES, INC.
Common Stock 		50,000,000
2018-01-09 3 SBBP Strongbridge Biopharma plc
Ordinary Shares, $0.01 par value 		8,282,616
2018-01-09 3 SBBP Strongbridge Biopharma plc
Ordinary Shares, $0.01 par value 		8,282,616
2017-11-27 2017-11-27 4 APPN APPIAN CORP
Class B Common Stock 		C - Conversion -569,620 2,724,202 -17.29
2017-11-27 2017-11-27 4 APPN APPIAN CORP
Class A Common Stock 		S - Sale -569,620 0 -100.00 19.49 -11,101,894
2017-11-27 2017-11-27 4 APPN APPIAN CORP
Class A Common Stock 		C - Conversion 569,620 569,620
2017-11-21 2017-11-20 4 APPN APPIAN CORP
Class B Common Stock 		C - Conversion -2,820,516 3,293,822 -46.13
2017-11-21 2017-11-20 4 APPN APPIAN CORP
Class A Common Stock 		S - Sale -2,820,516 0 -100.00 19.49 -54,971,857
2017-11-21 2017-11-20 4 APPN APPIAN CORP
Class A Common Stock 		C - Conversion 2,820,516 2,820,516
2017-11-20 3 ASNS Arsanis, Inc.
Common Stock 		4,000,000
2017-11-20 3 ASNS Arsanis, Inc.
Common Stock 		4,000,000
2017-08-30 2017-08-28 4 SYBX SYNLOGIC, INC.
Common Stock 		A - Award 3,394,439 3,818,940 799.63
2017-07-31 3 RGLS Regulus Therapeutics Inc.
Common Stock 		21,978,020
2017-07-31 3 RGLS Regulus Therapeutics Inc.
Common Stock 		21,978,020
2017-07-06 2017-07-03 4 MRSN Mersana Therapeutics, Inc.
Series C-1 Preferred Stock 		C - Conversion -2,216,626 0 -100.00
2017-07-06 2017-07-03 4 MRSN Mersana Therapeutics, Inc.
Series B-1 Preferred Stock 		C - Conversion -18,001,419 0 -100.00
2017-07-06 2017-07-03 4 MRSN Mersana Therapeutics, Inc.
Series A-1 Preferred Stock 		C - Conversion -11,931,173 0 -100.00
2017-07-06 2017-07-03 4 MRSN Mersana Therapeutics, Inc.
Common Stock 		P - Purchase 1,000,000 8,140,138 14.01 15.00 15,000,000 122,102,070
2017-07-06 2017-07-03 4 MRSN Mersana Therapeutics, Inc.
Common Stock 		C - Conversion 7,140,138 7,140,138
2017-05-31 2017-05-31 4 APPN APPIAN CORP
Class B Common Stock 		C - Conversion 6,114,338 6,114,338
2017-05-31 2017-05-31 4 APPN APPIAN CORP
Series B Convertible Preferred Stock 		C - Conversion -6,114,338 0 -100.00
2017-03-29 2017-03-28 4 AVEO AVEO PHARMACEUTICALS INC
Common Stock 		P - Purchase 6,000,000 16,362,694 57.90 0.50 3,000,000 8,181,347
2017-03-28 2017-03-27 4 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share 		P - Purchase 12,870,000 72,139,000 21.71 0.70 9,009,000 50,497,300
2017-03-22 2017-03-22 4 MULE MULESOFT, INC
Class B Common Stock 		J - Other 858,978 858,978
2017-03-22 2017-03-22 4 MULE MULESOFT, INC
Class B Common Stock 		J - Other 2,576,939 2,576,939
2017-03-22 2017-03-22 4 MULE MULESOFT, INC
Class B Common Stock 		J - Other 12,679,970 12,679,970
2017-03-22 2017-03-22 4 MULE MULESOFT, INC
Series G Preferred Stock 		C - Conversion -227,125 0 -100.00
2017-03-22 2017-03-22 4 MULE MULESOFT, INC
Series A Preferred Stock 		C - Conversion -631,853 0 -100.00
2017-03-22 2017-03-22 4 MULE MULESOFT, INC
Series G Preferred Stock 		C - Conversion -681,377 0 -100.00
2017-03-22 2017-03-22 4 MULE MULESOFT, INC
Series A Preferred Stock 		C - Conversion -1,895,562 0 -100.00
2017-03-22 2017-03-22 4 MULE MULESOFT, INC
Series G Preferred Stock 		C - Conversion -605,668 0 -100.00
2017-03-22 2017-03-22 4 MULE MULESOFT, INC
Series F Preferred Stock 		C - Conversion -2,064,048 0 -100.00
2017-03-22 2017-03-22 4 MULE MULESOFT, INC
Series E Preferred Stock 		C - Conversion -8,000,038 0 -100.00
2017-03-22 2017-03-22 4 MULE MULESOFT, INC
Series A Preferred Stock 		C - Conversion -1,689,436 0 -100.00
2017-03-22 2017-03-22 4 MULE MULESOFT, INC
Common Stock 		J - Other -858,978 0 -100.00
2017-03-22 2017-03-22 4 MULE MULESOFT, INC
Common Stock 		C - Conversion 858,978 858,978
2017-03-22 2017-03-22 4 MULE MULESOFT, INC
Common Stock 		J - Other -2,576,939 0 -100.00
2017-03-22 2017-03-22 4 MULE MULESOFT, INC
Common Stock 		C - Conversion 2,576,939 2,576,939
2017-03-22 2017-03-22 4 MULE MULESOFT, INC
Common Stock 		J - Other -12,679,970 0 -100.00
2017-03-22 2017-03-22 4 MULE MULESOFT, INC
Common Stock 		C - Conversion 12,359,190 12,679,970 3,852.86
2017-03-16 3 MULE MULESOFT, INC
Common Stock 		641,560
2017-03-16 3 MULE MULESOFT, INC
Common Stock 		641,560
2017-02-01 3 CASC Cascadian Therapeutics, Inc.
Common Stock 		18,129,148
2017-02-01 3 CASC Cascadian Therapeutics, Inc.
Common Stock 		18,129,148
2016-12-19 2016-12-19 4 AKAO Achaogen Inc
Common Stock 		P - Purchase 500,000 5,215,128 10.60 13.50 6,750,000 70,404,228
2016-12-19 2016-12-19 4 AKAO Achaogen Inc
Common Stock 		P - Purchase 500,000 5,215,128 10.60 13.50 6,750,000 70,404,228
2016-11-29 2016-11-29 4 TCON Tracon Pharmaceuticals, Inc.
Common Stock 		P - Purchase 869,565 2,758,039 46.05 5.75 4,999,999 15,858,724
2016-08-02 2016-07-29 4 ILIU INTERLEUKIN GENETICS INC
Common Stock Warrant (right to buy) 		P - Purchase 20,120,724 20,120,724
2016-08-02 2016-07-29 4 ILIU INTERLEUKIN GENETICS INC
Common Stock 		P - Purchase 20,120,724 55,418,811 57.00 0.10 2,000,000 5,508,630
2016-07-20 2016-07-18 4 ARDX ARDELYX, INC.
Common Stock 		P - Purchase 763,650 2,665,519 40.15 8.73 6,666,664 23,269,981
2016-07-20 2016-07-18 4 ARDX ARDELYX, INC.
Common Stock 		P - Purchase 763,651 2,665,520 40.15 8.73 6,666,673 23,269,990
2016-06-07 3 AKAO Achaogen Inc
Common Stock 		9,430,256
2016-06-07 3 AKAO Achaogen Inc
Common Stock 		9,430,256
2016-05-17 3 AVEO AVEO PHARMACEUTICALS INC
Common Stock 		20,725,388
2016-05-17 3 AVEO AVEO PHARMACEUTICALS INC
Common Stock 		20,725,388
2016-01-14 2016-01-13 4 ARDX ARDELYX, INC.
Common Stock 		P - Purchase 500,000 1,901,869 35.67 10.00 5,000,000 19,018,690
2016-01-14 2016-01-13 4 ARDX ARDELYX, INC.
Common Stock 		P - Purchase 500,000 1,901,869 35.67 10.00 5,000,000 19,018,690
2016-01-04 3 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share 		118,538,000
2016-01-04 3 ADAP Adaptimmune Therapeutics PLC
Ordinary Shares with a nominal value of 0.001 GBP per share 		118,538,000
2015-10-20 2015-10-20 4 CERC Cerecor Inc.
Series B Convertible Preferred Stock 		C - Conversion -16,638,880 0 -100.00
2015-10-20 2015-10-20 4 CERC Cerecor Inc.
Common Stock 		C - Conversion 594,245 594,245
2015-10-06 2015-10-06 4 MIRN Mirna Therapeutics, Inc.
Common Stock 		P - Purchase 857,142 2,971,517 40.54 7.00 5,999,994 20,800,619
2015-10-06 2015-10-06 4 MIRN Mirna Therapeutics, Inc.
Common Stock 		J - Other 31,650 2,114,375 1.52
2015-10-06 2015-10-06 4 MIRN Mirna Therapeutics, Inc.
Common Stock 		J - Other 257,516 1,499,166 20.74
2015-10-06 2015-10-05 4 MIRN Mirna Therapeutics, Inc.
Series D Preferred Stock 		C - Conversion -583,559 0 -100.00
2015-10-06 2015-10-05 4 MIRN Mirna Therapeutics, Inc.
Series C Preferred Stock 		C - Conversion -1,241,650 0 -100.00
2015-10-06 2015-10-05 4 MIRN Mirna Therapeutics, Inc.
Common Stock 		C - Conversion 583,559 2,082,725 38.93
2015-10-06 2015-10-05 4 MIRN Mirna Therapeutics, Inc.
Common Stock 		C - Conversion 1,241,650 1,241,650
2015-06-17 3 ABIO ARCA biopharma, Inc.
Common Stock 		20,442,930
2015-06-17 3 ABIO ARCA biopharma, Inc.
Common Stock 		20,442,930
2015-06-09 3 ARDX ARDELYX, INC.
Common Stock 		4,205,607
2015-06-09 3 ARDX ARDELYX, INC.
Common Stock 		4,205,607
2015-06-09 3 ARDX ARDELYX, INC.
Common Stock 		4,205,607
2015-06-09 3 ARDX ARDELYX, INC.
Common Stock 		4,205,607
2015-03-24 3 CSBR CHAMPIONS ONCOLOGY, INC.
Common Stock 		37,500,000
2015-03-24 3 CSBR CHAMPIONS ONCOLOGY, INC.
Common Stock 		37,500,000
2015-02-05 2015-02-04 4 TCON Tracon Pharmaceuticals, Inc.
Series B Redeemable Convertible Preferred Stock 		C - Conversion -5,373,396 0 -100.00
2015-02-05 2015-02-04 4 TCON Tracon Pharmaceuticals, Inc.
Common Stock 		P - Purchase 500,000 1,888,474 36.01 10.00 5,000,000 18,884,740
2015-02-05 2015-02-04 4 TCON Tracon Pharmaceuticals, Inc.
Common Stock 		C - Conversion 1,388,474 1,388,474
2014-12-29 2014-12-23 4 ILIU INTERLEUKIN GENETICS INC
Common Stock Warrant (right to buy) 		P - Purchase 19,868,965 19,868,965
2014-12-29 2014-12-23 4 ILIU INTERLEUKIN GENETICS INC
Common Stock 		P - Purchase 19,868,965 35,298,087 128.78 0.10 1,992,857 3,540,398
2014-08-06 2014-08-06 4 LOXO Loxo Oncology, Inc.
Series B Convertible Preferred Stock 		C - Conversion -1,558,651 0 -100.00
2014-08-06 2014-08-06 4 LOXO Loxo Oncology, Inc.
Common Stock 		P - Purchase 230,769 1,789,420 14.81 13.00 2,999,997 23,262,460
2014-08-06 2014-08-06 4 LOXO Loxo Oncology, Inc.
Common Stock 		C - Conversion 1,558,651 1,558,651
2013-05-23 3 ILIU INTERLEUKIN GENETICS INC
Common Stock 		15,429,122
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)